Navigation Links
Study to Investigate Gene's Effect on Bone Loss in Breast Cancer Patients

Women with estrogen-responsive breast cancer are often prescribed a drug that reduces their estrogen levels. But because estrogen is important to bone health, there is widespread concern about how the estrogen-reducing drugs - called aromatase inhibitors - affect bones.

A study at Washington University School of Medicine in St. Louis will investigate bone loss in women taking aromatase inhibitors, and researchers are calling for interested women to volunteer.

Aromatase is an enzyme that transforms testosterone and other androgens into estrogen. This process represents the major, if not only, source of estrogen in postmenopausal women. So giving women aromatase inhibitors can result in nearly complete shutdown of estrogen production, which can have unwanted side effects.

"There are reports of an increased incidence of fractures in women on aromatase inhibitors," says Reina Armamento-Villareal, M.D., assistant professor of medicine in the Division of Bone and Mineral Diseases and a Washington University bone specialist at Barnes-Jewish Hospital. "But interestingly, studies show that women respond differently to these drugs, possibly because of variations in the gene that produces the aromatase enzyme."

This gene is CYP19. Scientists have identified several variations of CYP19 that can result in either increased or decreased aromatase activity. This in turn influences how aromatase inhibitors affect estrogen levels. The Washington University study will analyze the sequence of the CYP19 gene in volunteers to see which variation they possess.

"Our hypothesis is that the use of aromatase inhibitors can be associated with significant bone loss, and the degree of bone loss will be related to the variations of the CYP19 gene," Villareal says.

The data the researchers collect from the study will aid in establishing the appropriate approach to maintaining bone health in women who are given aromatase inhib itors. This study is an example of how physicians hope to use a patient's genetic code to create personalized treatment.

"As more breast cancer patients use these drugs, more may be expected to experience osteoporotic (porous bone) complications," Villareal says. "We are attempting to address this issue to identify those that would need early intervention to prevent bone loss with aromatase inhibitor therapy."

Postmenopausal women with breast cancer are eligible to participate. The researchers will compare bone loss in women taking aromatase inhibitors to those not using these drugs, so both groups are wanted for the study. The study will not require participants to alter their cancer treatment.

Participants will receive free bone density scans and will be tested for blood markers that indicate bone turnover. Each volunteer will be genotyped for CYP19 variants to investigate any link between genetic profile and bone loss.


'"/>




Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... NY (PRWEB) , ... April 28, 2017 , ... It's ... there are a number of illnesses that are unclear as to whether or not ... their heads. Bronchitis is one of these illnesses. So, FindaTopDoc took a look into ...
(Date:4/28/2017)... ... ... affects much more than energy – it also has mental and physical benefits. According to ... time, which can increase the risk of having a car accident. , This week ... to help you sleep better and feel better:, , Turn off ...
(Date:4/28/2017)... ... , ... The Radiology Business Management Association (RBMA) is pleased to ... election process has been in place since the RBMA was founded in 1968 with ... succeeds Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... America (UCAOA) and College of Urgent Care Medicine will host industry leaders for ... and speakers will help those in the industry adapt to the issues currently ...
(Date:4/28/2017)... ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh ... Creator responds to and which He does not. Yisrayl says with so many titles ... the true name, but he says with a little Scripture, backed with a lot of ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... EAST HANOVER, N.J. , April 19, 2017 ... study conducted by the National Heart, Lung, and ... Health (NIH) demonstrating that 58% of patients with ... at six months when treated with eltrombopag at ... treatment 1 . The study evaluated three sequential ...
(Date:4/18/2017)... April 18, 2017  Cardinal Health (NYSE: ... fiscal 2017 earnings per share (EPS) guidance and providing ... is in conjunction with this morning,s announcement of the ... and Nutritional Insufficiency businesses. Cardinal Health now ... will be at the bottom of its previous guidance ...
(Date:4/18/2017)... Viverae ® , a leader in workplace ... IBM ® Watson Campaign Automation, implementing behavioral messaging ... a personalized experience. Through digital engagement, the platform prompts ... real time. The enhanced experience drives engagement by focusing ... they are in their journey to health. ...
Breaking Medicine Technology: